Clinical Trials Logo

Aspergillosis clinical trials

View clinical trials related to Aspergillosis.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05045391 Active, not recruiting - Aspergillosis Clinical Trials

Pulmonary Aspergillosis in Tuberculosis Patients

Start date: January 1, 2020
Phase:
Study type: Observational

Pulmonary tuberculosis (PTB) is the most common cause of lung destruction, contributing to coinfections development, and Aspergillosis spp. is one of the most important. Diagnosis of chronic pulmonary aspergillosis (CPA) in PTB patients is difficult due to similarity of clinical and radiological data, especially in resource-constrained settings. Differentiation of PTB patients with singling out a group with a higher Aspergillus IgG level during the initial examination will help physicians to orient to further examination of CPA. Objectives: to determine the prevalence of aspergillosis in Koch's bacillus-positive and Koch's bacillus-negative PTB patients and antifungal resistance of Aspergillus species isolates in Central Asia countries.

NCT ID: NCT04227483 Active, not recruiting - Clinical trials for Allergic Bronchopulmonary Aspergillosis

Deflazacort vs. Prednisolone in Acute-stage ABPA

Start date: January 15, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

Oral glucocorticoids are currently the treatment of choice for allergic bronchopulmonary aspergillosis (ABPA). They not only suppress the immune hyperfunction but are also anti-inflammatory. Unfortunately, numerous toxicities and adverse effects have been attributed to glucocorticoids related to both the average dose and cumulative duration of use. Deflazacort is a oxazoline steroid with demonstrated anti-inflammatory and immunosuppressant effects. The novel structural characteristic of deflazacort is associated with substantial lack of sodium-retaining activity, lower interference with carbohydrate metabolism and calcium metabolism in comparison with older glucocorticoids such as prednisolone. The investigators hypothesize that the occurrence of side-effects, primarily weight gain will be lower with deflazacort. In this study, the investigators will compare the safety and efficacy of deflazacort in the treatment of acute-stage ABPA complicating asthma.

NCT ID: NCT01176071 Active, not recruiting - Clinical trials for Invasive Aspergillosis

Correlation Between Circulating Galactomannan and Beta-D-glucan and Clinical Outcome of Invasive Aspergillosis

Start date: July 2010
Phase: N/A
Study type: Observational

The investigators hypothesize that early galactomannan and beta-D-glucan features, namely the height of the initial value at the time of diagnosis and the subsequent rate of marker decay within the first week(s) following therapy (day 7, day 14) are important factors in predicting clinical outcome.

NCT ID: NCT00838643 Active, not recruiting - Clinical trials for Invasive Aspergillosis

Invasive Aspergillosis After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Start date: May 2002
Phase: N/A
Study type: Observational

Evaluation of incidence of invasive aspergillosis in patients who have undergone an allogeneic stem cell transplantation, with particular regard to the role of galactomannan assay and of early TC scan in asymptomatic patients.